. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Pharm Res. 2015 Mar 21;32(9):2960–2972. doi: 10.1007/s11095-015-1678-2

Table 4.

Inhibitory activity of film-formulated EFdA, CSIC and 1:1 combinations against wild type and drug-resistant HIV variants.

Virus	EFdA EC₅₀ (nM)	CSIC EC₅₀ (nM)	Combination EC₅₀^a (nM)	C.I.₅₀^b
Wild type	3.7 ± 0.3	1.2 ± 0.1	1.7 ± 0.3	0.95 (additive)
M184V	18.2 ± 0.3	1.6 ± 0.4	3.8 ± 0.2	1.2 (additive)
L100I/K103N	3.8 ± 0.5	435 ± 40	9.3 ± 0.6	1.2 (additive)

: Combination films contained EFdA and CSIC at 1:1 molar ratio

: Combination Index at 50% inhibition (mutually non-exclusive) calculated as described²³